Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12660780 | 1.00 | USP2 (0.49) | USP2SMN1; SMN2RECQLALDH1A1ATM | |
| SCHEMBL2206068 | 1.00 | USP2 (0.49) | USP2SMN1; SMN2RECQLALDH1A1ATM | |
| SCHEMBL31148682 | 0.91 | SMN1; SMN2 (0.43) | USP2SMN1; SMN2RECQLALDH1A1ATM | |
| SCHEMBL5783722 | 0.89 | SMN1; SMN2 (0.40) | USP2SMN1; SMN2RECQLALDH1A1PDK1 | |
| SCHEMBL5782176 | 0.88 | USP2 (0.39) | USP2SMN1; SMN2RECQLALDH1A1ATM | |
| SCHEMBL24923288 | 0.87 | USP2 (0.47) | USP2SMN1; SMN2RECQLATMTSHR | |
| SCHEMBL15561483 | 0.87 | USP2 (0.47) | USP2SMN1; SMN2RECQLATMTSHR | |
| SCHEMBL27041563 | 0.87 | USP2 (0.47) | USP2SMN1; SMN2RECQLATM | |
| SCHEMBL15561481 | 0.87 | USP2 (0.47) | USP2SMN1; SMN2RECQLATMTSHR | |
| SCHEMBL27041560 | 0.87 | USP2 (0.47) | USP2SMN1; SMN2RECQLATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124214-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2026-05-07 | — | — | US | disclosed |
| EP-4731626-A1 | PI3K INHIBITORS AND USE THEREOF | Regor Pharmaceuticals, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4653438-A1 | MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2025-11-26 | — | — | EP | disclosed |
| EP-4640279-A2 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2025-10-29 | — | — | EP | disclosed |
| EP-4356969-B1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2025-07-09 | — | — | EP | disclosed |
| US-20250163030-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2025-05-22 | — | — | US | disclosed |
| WO-2025067111-A1 | MENIN-MLL INTERACTION INHIBITOR AND PREPARATION METHOD THEREFOR, AND APPLICATION | 苏州必扬医药科技有限公司 | 2025-04-03 | — | — | WO | disclosed |
| US-20250011334-A1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2025-01-09 | — | — | US | disclosed |
| WO-2024260464-A1 | PI3K INHIBITORS AND USE THEREOF | REGOR PHARMACEUTICALS, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| CN-113683614-B | Fused tricyclic pyridazinone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| WO-2015078392-A1 | PROCESSES FOR PREPARING DIHYDROPYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015078393-A1 | PROCESSES FOR PREPARING DIHYDROPYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-06-04 | — | — | WO | disclosed |
| WO-2008048589-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF HCV | XTL BIOPHARMACEUTICALS LTD (US) | 2008-04-24 | — | — | WO | disclosed |
| CN-1255401-C | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2006-05-10 | — | — | CN | disclosed |
| US-6924278-B2 | Heterocyclic carboxy amines such as (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[4-((3S)-3-ethylmorpholino)-2-butynyl]-2-[(1H-indol-3-yl)methyl]piperazine, used as substance P and neurokinin antagonist for prophylaxis of diseases | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20050027121-A1 | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-02-03 | — | — | US | disclosed |
| US-20030114668-A1 | AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-19 | — | — | US | disclosed |
| CN-1266431-A | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-09-13 | — | — | CN | disclosed |
| EP-0993457-A1 | AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-19 | — | — | EP | disclosed |
| WO-1998057954-A1 | AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124214-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CBR1, NR3C1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | USP2 4498/4885SMN1; SMN2 2272/4885RECQL 1812/4885 |
| US-20050027121-A1 | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | TAC3, TACR1, SSTR5 | USP2 3424/4885SMN1; SMN2 4315/4885RECQL 4557/4885 |
| US-20250011334-A1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | ZC3HAV1, ZC3HAV1L, CUL1 | USP2 3222/4885SMN1; SMN2 773/4885RECQL 192/4885 |
| US-20250163030-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | PIR, CYP3A43, CYP1A2 | USP2 4299/4885SMN1; SMN2 2003/4885RECQL 2267/4885 |
| US-20030114668-A1 | AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | TACR1, NPSR1, SSTR2 | USP2 3514/4885SMN1; SMN2 4534/4885RECQL 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.